Fixed Treatment Duration Mosunetuzumab in Patients With Relapsed or Refractory Follicular Lymphoma: Perspectives From...

Mosunetuzumab is a CD20xCD3 T-cell engaging bispecific antibody that has demonstrated a manageable safety profile in patients with relapsed or refractory (R/R) non-Hodgkin lymphoma in a pivotal phase II study (GO29781; NCT02500407). Rapid identification and appropriate management of adverse events (AEs) are key for patients receiving mosunetuzumab, and advanced practice providers (APPs) play a vital role.

Six APPs were surveyed, including nurse practitioners, a research nurse, clinical pharmacists, and physician assistants, from four US academic centers involved in the phase II GO29781 study of mosunetuzumab administered intravenously in patients with R/R follicular lymphoma. Advanced practice providers provided their perspectives and experiences on their roles in the education of staff and patients, and in the monitoring and management of AEs associated with mosunetuzumab treatment.

APPs provided education to staff and patients around the signs and symptoms of potential AEs as well as mosunetuzumab's mechanism of action, route of administration, and dosing schedule. They were involved in monitoring patients for AEs using clinical assessments and laboratory tests and were responsible for managing AEs, ordering necessary interventions, deciding when to interrupt treatment, clearing patients for their next dose, and advising the wider medical team on steps for patient management.

APPs play a key role as part of a multidisciplinary team to ensure the safety and comfort of patients receiving mosunetuzumab in the outpatient setting. The APP experiences presented here may be used to inform future clinical practice and care coordination for mosunetuzumab treatment.